<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38488365</PMID><DateCompleted><Year>2024</Year><Month>04</Month><Day>08</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2165-0497</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>Apr</Month><Day>02</Day></PubDate></JournalIssue><Title>Microbiology spectrum</Title><ISOAbbreviation>Microbiol Spectr</ISOAbbreviation></Journal><ArticleTitle>SARS-CoV-2 pandemic non-pharmacologic interventions temporally associated with reduced pediatric infections due to <i>Mycoplasma pneumoniae</i> and co-infecting respiratory viruses in Arkansas.</ArticleTitle><Pagination><StartPage>e0290823</StartPage><MedlinePgn>e0290823</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e02908-23</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1128/spectrum.02908-23</ELocationID><Abstract><AbstractText Label="UNLABELLED">Non-pharmacologic interventions (NPIs), such as universal masking, implemented during the SARS-CoV-2 pandemic have reduced respiratory infections among children. This study evaluated the impact of NPIs on <i>Mycoplasma pneumoniae</i> infections in children, analyzing data from two hospitals in Arkansas and examining age-related differences and co-infections with other respiratory viruses. The study was approved by the Institutional Review Board and included patients (≤18 years) with upper respiratory tract symptoms. Data generated from the FilmArray Respiratory Panel were divided into pre-NPI, NPI, and post-NPI periods for analysis. Overall test positivity rate and positivity rate interval changes were evaluated. Statistical differences were determined by Chi-square (χ<sup>2</sup> independence) analysis. A total of 100,077 tests were performed, with a statistical increase in testing volume during the NPI and post-NPI periods. The number of positive <i>M. pneumoniae</i> tests decreased by 77% (77 to 18) during the NPI period, then increased by 50% (18 to 27) during the post-NPI period. Preschool and elementary school age groups had the highest number of positive tests during the study at 59 (48%) and 40 (33%), respectively. Reduced <i>M. pneumoniae</i> infections were consistent across age groups. Co-infections with other respiratory viruses, particularly human rhinovirus/enterovirus, were observed at much lower levels. Pediatric <i>M. pneumoniae</i> infections in Arkansas were temporally associated with implementation and discontinuation of NPIs. Specific viral co-infections still occurred, albeit at lower levels during the SARS-CoV-2 pandemic. Because of the slower growth of this bacterium, we expect <i>M. pneumoniae</i> infections to return to pre-pandemic levels within approximately 2 years.</AbstractText><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Non-pharmacologic interventions (NPIs) effectively curtailed the spread of SARS-CoV-2 and, fortuitously, many other aerosol-transmitted respiratory pathogens. This study included the largest data set of symptomatic, pediatric patients from within the United States spanning a period from November 2017 through December 2023, and encompassed individuals residing in both rural and urban settings. We observed a strong correlation between the implementation and cessation of NPIs with the rate of respiratory infections due to <i>Mycoplasma pneumoniae</i> and viral co-infections. These infections are returning to baseline levels approximately 2 years following NPI cessation. This observation was not unexpected since the replication time for viruses is exponentially faster than that of bacteria. The resurgence of <i>M. pneumoniae</i> and likely other atypical bacterial pathogens is currently in process. Healthcare providers should strongly consider these pathogens in individuals presenting with respiratory tract illnesses.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Boyanton</LastName><ForeName>Bobby L</ForeName><Initials>BL</Initials><Suffix>Jr</Suffix><Identifier Source="ORCID">0000-0002-5665-7357</Identifier><AffiliationInfo><Affiliation>Department of Pathology, Arkansas Children's Hospital, Little Rock, Arkansas, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frenner</LastName><ForeName>Rachel A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Pathology, Arkansas Children's Hospital, Little Rock, Arkansas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ingold</LastName><ForeName>Ashton</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Arkansas Children's Research Institute, Little Rock, Arkansas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ambroggio</LastName><ForeName>Lilliam</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-6242-607X</Identifier><AffiliationInfo><Affiliation>Sections of Emergency Medicine and Hospital Medicine, Children's Hospital Colorado, Aurora, Colorado, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, University of Colorado, Aurora, Colorado, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kennedy</LastName><ForeName>Joshua L</ForeName><Initials>JL</Initials><Identifier Source="ORCID">0000-0002-1919-9051</Identifier><AffiliationInfo><Affiliation>Arkansas Children's Research Institute, Little Rock, Arkansas, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departments of Pediatrics and Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P20 GM121293</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>03</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Microbiol Spectr</MedlineTA><NlmUniqueID>101634614</NlmUniqueID><ISSNLinking>2165-0497</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>medRxiv. 2023 Aug 09:2023.08.05.23293566. doi: 10.1101/2023.08.05.23293566</RefSource><PMID Version="1">37609274</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001131" MajorTopicYN="N" Type="Geographic">Arkansas</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009177" MajorTopicYN="N">Mycoplasma pneumoniae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060085" MajorTopicYN="Y">Coinfection</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012141" MajorTopicYN="Y">Respiratory Tract Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">NPI</Keyword><Keyword MajorTopicYN="N">infection control</Keyword><Keyword MajorTopicYN="N">severe acute respiratory syndrome coronavirus 2</Keyword><Keyword MajorTopicYN="N">social distancing</Keyword><Keyword MajorTopicYN="N">universal masking</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>3</Month><Day>15</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>3</Month><Day>15</Day><Hour>9</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>3</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38488365</ArticleId><ArticleId IdType="pmc">PMC10986484</ArticleId><ArticleId IdType="doi">10.1128/spectrum.02908-23</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cowling BJ, Ali ST, Ng TWY, Tsang TK, Li JCM, Fong MW, Liao Q, Kwan MY, Lee SL, Chiu SS, Wu JT, Wu P, Leung GM. 2020. Impact assessment of non-pharmaceutical interventions against coronavirus disease 2019 and influenza in Hong Kong: an observational study. Lancet Public Health 5:e279–e288. doi:10.1016/S2468-2667(20)30090-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-2667(20)30090-6</ArticleId><ArticleId IdType="pmc">PMC7164922</ArticleId><ArticleId IdType="pubmed">32311320</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyanton BL Jr, Snowden JN, Frenner RA, Rosenbaum ER, Young HL, Kennedy JL. 2023. SARS-CoV-2 infection mitigation strategies concomitantly reduce group a Streptococcus pharyngitis. Clin Pediatr (Phila) 62:683–687. doi:10.1177/00099228221141534</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/00099228221141534</ArticleId><ArticleId IdType="pmc">PMC9747366</ArticleId><ArticleId IdType="pubmed">36495165</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsen SJ, Winn AK, Budd AP, Prill MM, Steel J, Midgley CM, Kniss K, Burns E, Rowe T, Foust A, et al. . 2021. Changes in influenza and other respiratory virus activity during the COVID-19 pandemic - United States, 2020-2021. MMWR Morb Mortal Wkly Rep 70:1013–1019. doi:10.15585/mmwr.mm7029a1</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7029a1</ArticleId><ArticleId IdType="pmc">PMC8297694</ArticleId><ArticleId IdType="pubmed">34292924</ArticleId></ArticleIdList></Reference><Reference><Citation>McBride JA, Eickhoff J, Wald ER. 2020. Impact of COVID-19 quarantine and school cancelation on other common infectious diseases. Pediatr Infect Dis J 39:e449–e452. doi:10.1097/INF.0000000000002883</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000002883</ArticleId><ArticleId IdType="pubmed">33031142</ArticleId></ArticleIdList></Reference><Reference><Citation>Torretta S, Capaccio P, Coro I, Bosis S, Pace ME, Bosi P, Pignataro L, Marchisio P. 2021. Incidental lowering of otitis-media complaints in otitis-prone children during COVID-19 pandemic: not all evil comes to hurt. Eur J Pediatr 180:649–652. doi:10.1007/s00431-020-03747-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00431-020-03747-9</ArticleId><ArticleId IdType="pmc">PMC7370867</ArticleId><ArticleId IdType="pubmed">32691131</ArticleId></ArticleIdList></Reference><Reference><Citation>McNeil JC, Flores AR, Kaplan SL, Hulten KG. 2021. The indirect impact of the SARS-CoV-2 pandemic on invasive group a Streptococcus, Streptococcus pneumoniae and Staphylococcus aureus infections in Houston area children. Pediatr Infect Dis J 40:e313–e316. doi:10.1097/INF.0000000000003195</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000003195</ArticleId><ArticleId IdType="pmc">PMC8279221</ArticleId><ArticleId IdType="pubmed">34250979</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalabih A, Young HL, Frenner RA, Stroud MH, Boyanton BL. 2022. SARS-CoV-2 prevention measures concomitantly attenuate methicillin-resistant Staphylococcus aureus infection rates. Clin Pediatr (Phila) 61:137–140. doi:10.1177/00099228211067898</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/00099228211067898</ArticleId><ArticleId IdType="pubmed">35132903</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatoun J, Correa ET, Donahue SMA, Vernacchio L. 2020. Social distancing for COVID-19 and diagnoses of other infectious diseases in children. Pediatrics 146:e2020006460. doi:10.1542/peds.2020-006460</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2020-006460</ArticleId><ArticleId IdType="pubmed">32879032</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakamoto H, Ishikane M, Ueda P. 2020. Seasonal influenza activity during the SARS-CoV-2 outbreak in Japan. JAMA 323:1969–1971. doi:10.1001/jama.2020.6173</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.6173</ArticleId><ArticleId IdType="pmc">PMC7149351</ArticleId><ArticleId IdType="pubmed">32275293</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan SG, Carlson S, Cheng AC, Chilver MB, Dwyer DE, Irwin M, Kok J, Macartney K, MacLachlan J, Minney-Smith C, Smith D, Stocks N, Taylor J, Barr IG. 2020. Where has all the influenza gone? the impact of COVID-19 on the circulation of influenza and other respiratory viruses. Euro Surveill 25:2001847. doi:10.2807/1560-7917.ES.2020.25.47.2001847</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2020.25.47.2001847</ArticleId><ArticleId IdType="pmc">PMC7693168</ArticleId><ArticleId IdType="pubmed">33243355</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh DY, Buda S, Biere B, Reiche J, Schlosser F, Duwe S, Wedde M, von Kleist M, Mielke M, Wolff T, Dürrwald R. 2021. Trends in respiratory virus circulation following COVID-19-targeted nonpharmaceutical interventions in Germany, January–September 2020: analysis of national surveillance data. Lancet Reg Health Eur 6:100112. doi:10.1016/j.lanepe.2021.100112</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2021.100112</ArticleId><ArticleId IdType="pmc">PMC8183189</ArticleId><ArticleId IdType="pubmed">34124707</ArticleId></ArticleIdList></Reference><Reference><Citation>Rybak A, Levy C, Angoulvant F, Auvrignon A, Gembara P, Danis K, Vaux S, Levy-Bruhl D, van der Werf S, Béchet S, Bonacorsi S, Assad Z, Lazzati A, Michel M, Kaguelidou F, Faye A, Cohen R, Varon E, Ouldali N. 2022. Association of nonpharmaceutical interventions during the COVID-19 pandemic with invasive pneumococcal disease, pneumococcal carriage, and respiratory viral infections among children in France. JAMA Netw Open 5:e2218959. doi:10.1001/jamanetworkopen.2022.18959</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.18959</ArticleId><ArticleId IdType="pmc">PMC9240903</ArticleId><ArticleId IdType="pubmed">35763298</ArticleId></ArticleIdList></Reference><Reference><Citation>Angoulvant F, Ouldali N, Yang DD, Filser M, Gajdos V, Rybak A, Guedj R, Soussan-Banini V, Basmaci R, Lefevre-Utile A, Brun-Ney D, Beaujouan L, Skurnik D. 2021. Coronavirus disease 2019 pandemic: impact caused by school closure and national lockdown on pediatric visits and admissions for viral and nonviral infections—a time series analysis. Clin Infect Dis 72:319–322. doi:10.1093/cid/ciaa710</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa710</ArticleId><ArticleId IdType="pmc">PMC7314162</ArticleId><ArticleId IdType="pubmed">33501967</ArticleId></ArticleIdList></Reference><Reference><Citation>Oster Y, Michael-Gayego A, Rivkin M, Levinson L, Wolf DG, Nir-Paz R. 2020. Decreased prevalence rate of respiratory pathogens in hospitalized patients during the COVID-19 pandemic: possible role for public health containment measures Clin Microbiol Infect 27:811–812. doi:10.1016/j.cmi.2020.12.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2020.12.007</ArticleId><ArticleId IdType="pmc">PMC7833997</ArticleId><ArticleId IdType="pubmed">33352303</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer Sauteur PM, Beeton ML, Uldum SA, Bossuyt N, Vermeulen M, Loens K, Pereyre S, Bébéar C, Keše D, Day J, Afshar B, Chalker VJ, Greub G, Nir-Paz R, Dumke R, ESGMAC–MyCOVID Study Team . 2022. Mycoplasma pneumoniae detections before and during the COVID-19 pandemic: results of a global survey, 2017 to 2021. Euro Surveill 27:2100746. doi:10.2807/1560-7917.ES.2022.27.19.2100746</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2022.27.19.2100746</ArticleId><ArticleId IdType="pmc">PMC9101966</ArticleId><ArticleId IdType="pubmed">35551702</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer Sauteur PM, Chalker VJ, Berger C, et al. , ESGMAC and the ESGMAC–MyCOVID study group . 2022. Mycoplasma pneumoniae beyond the COVID-19 pandemic: where is it? Lancet Microbe 3:e897. doi:10.1016/S2666-5247(22)00190-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(22)00190-2</ArticleId><ArticleId IdType="pmc">PMC9371584</ArticleId><ArticleId IdType="pubmed">35964636</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng Y, Cheng Y, Dai S, Hou D, Ge M, Zhang Y, Fan L, Pei Y, Yu L, Xue G, Ma L, Sun H. 2022. The prevalence of Mycoplasma pneumoniae among children in Beijing before and during the COVID-19 pandemic. Front Cell Infect Microbiol 12:854505. doi:10.3389/fcimb.2022.854505</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2022.854505</ArticleId><ArticleId IdType="pmc">PMC9103471</ArticleId><ArticleId IdType="pubmed">35573799</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Li T, Chen N, Kang P, Yang J. 2023. Changes of Mycoplasma pneumoniae prevalence in children before and after COVID-19 pandemic in Henan, China. J Infect 86:256–308. doi:10.1016/j.jinf.2022.12.030</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2022.12.030</ArticleId><ArticleId IdType="pmc">PMC9838080</ArticleId><ArticleId IdType="pubmed">36646141</ArticleId></ArticleIdList></Reference><Reference><Citation>Haapanen M, Renko M, Artama M, Kuitunen I. 2021. The impact of the lockdown and the re-opening of schools and day cares on the epidemiology of SARS-CoV-2 and other respiratory infections in children—a nationwide register study in Finland. EClinicalMedicine 34:100807. doi:10.1016/j.eclinm.2021.100807</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.100807</ArticleId><ArticleId IdType="pmc">PMC8007090</ArticleId><ArticleId IdType="pubmed">33817612</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Huang Y, Ai T, Luo J, Liu H. 2021. Effect of COVID-19 on childhood Mycoplasma pneumoniae infection in Chengdu, China. BMC Pediatr 21. doi:10.1186/s12887-021-02679-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12887-021-02679-z</ArticleId><ArticleId IdType="pmc">PMC8079841</ArticleId><ArticleId IdType="pubmed">33910509</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuitunen I. 2022. Bordetella pertussis,Chlamydia pneumoniae, and Mycoplasma pneumoniae findings in children during COVID-19 pandemic in Finland. SN Compr Clin Med 4. doi:10.1007/s42399-022-01251-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s42399-022-01251-9</ArticleId><ArticleId IdType="pmc">PMC9281357</ArticleId><ArticleId IdType="pubmed">35856013</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Y-J, Wang S-M, Cho Y-H, Shen C-F, Liu C-C, Chi H, Huang Y-C, Huang L-M, Huang Y-C, Lin H-C, Ho Y-H, Mu J-J, Taiwan Pediatric Infectious Disease Alliance . 2015. Clinical and epidemiological characteristics in children with community-acquired Mycoplasma pneumonia in Taiwan: a nationwide surveillance. J Microbiol Immunol Infect 48:632–638. doi:10.1016/j.jmii.2014.08.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmii.2014.08.003</ArticleId><ArticleId IdType="pubmed">25311405</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng X, Lee S, Selvarangan R, Qin X, Tang Y-W, Stiles J, Hong T, Todd K, Ratliff AE, Crabb DM, Xiao L, Atkinson TP, Waites KB. 2015. Macrolide-resistant Mycoplasma Pneumoniae, United States1. Emerg Infect Dis 21:1470–1472. doi:10.3201/eid2108.150273</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2108.150273</ArticleId><ArticleId IdType="pmc">PMC4517703</ArticleId><ArticleId IdType="pubmed">26196107</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaz MH, Cross KE, Benitez AJ, Hicks LA, Kutty P, Bramley AM, Chappell JD, Hymas W, Patel A, Qi C, Williams DJ, Arnold SR, Ampofo K, Self WH, Grijalva CG, Anderson EJ, McCullers JA, Pavia AT, Wunderink RG, Edwards KM, Jain S, Winchell JM. 2016. Identification of bacterial and viral codetections with Mycoplasma pneumoniae using the Taqman array card in patients hospitalized with community-acquired pneumonia. Open Forum Infect Dis 3:ofw071. doi:10.1093/ofid/ofw071</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofw071</ArticleId><ArticleId IdType="pmc">PMC4867659</ArticleId><ArticleId IdType="pubmed">27191004</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Chen Z, Gu W, Ji W, Wang Y, Hao C, He Y, Huang L, Wang M, Shao X, Yan Y. 2018. Viral and bacterial co-infection in hospitalised children with refractory Mycoplasma pneumoniae pneumonia. Epidemiol Infect 146:1384–1388. doi:10.1017/S0950268818000778</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0950268818000778</ArticleId><ArticleId IdType="pmc">PMC9133674</ArticleId><ArticleId IdType="pubmed">29970200</ArticleId></ArticleIdList></Reference><Reference><Citation>Kutty PK, Jain S, Taylor TH, Bramley AM, Diaz MH, Ampofo K, Arnold SR, Williams DJ, Edwards KM, McCullers JA, Pavia AT, Winchell JM, Schrag SJ, Hicks LA. 2019. Mycoplasma pneumoniae among children hospitalized with community-acquired pneumonia. Clin Infect Dis 68:5–12. doi:10.1093/cid/ciy419</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciy419</ArticleId><ArticleId IdType="pmc">PMC6552676</ArticleId><ArticleId IdType="pubmed">29788037</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Wang J, Chen W, Shen N, Tao Y, Zhao R, Luo L, Li B, Cao Q. 2020. Impact of viral coinfection and macrolide-resistant mycoplasma infection in children with refractory Mycoplasma pneumoniae pneumonia. BMC Infect Dis 20. doi:10.1186/s12879-020-05356-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-020-05356-1</ArticleId><ArticleId IdType="pmc">PMC7447613</ArticleId><ArticleId IdType="pubmed">32847534</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Q, Li L, Wang C, Huang Y, Ma F, Cong S, Tan J, Yao L, Chen A, Zheng L. 2022. Comprehensive virome analysis of the viral spectrum in paediatric patients diagnosed with Mycoplasma pneumoniae pneumonia. Virol J 19:181. doi:10.1186/s12985-022-01914-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-022-01914-y</ArticleId><ArticleId IdType="pmc">PMC9644017</ArticleId><ArticleId IdType="pubmed">36352436</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi HJ, Kim NY, Eom SA, Kim-Jeon MD, Oh SS, Moon BS, Kwon MJ, Eom JS. 2022. Effects of non-pharmacological interventions on respiratory viruses other than SARS-CoV-2: analysis of laboratory surveillance and literature review from 2018 to 2021. J Korean Med Sci 37:e172. doi:10.3346/jkms.2022.37.e172</Citation><ArticleIdList><ArticleId IdType="doi">10.3346/jkms.2022.37.e172</ArticleId><ArticleId IdType="pmc">PMC9151990</ArticleId><ArticleId IdType="pubmed">35638198</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>